CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of its first patient in a Phase I clinical study for its recombinant polio vaccine in Australia.
This candidate vaccine is a non-infectious virus-like particle (VLP) formulation, developed utilizing CanSino’s proprietary protein structure design and VLP assembly technology. Unlike traditional vaccines that use live viruses, this innovative approach is expected to offer enhanced safety and immunogenicity. The World Health Organization has recommended this non-communicable VLP poliomyelitis vaccine as a preferred option for future polio eradication efforts, distinguishing it from already marketed attenuated and inactivated versions.- Flcube.com
